Paratek Pharmaceuticals is focused on developing innovative solutions to combat antimicrobial resistance (AMR), a significant global health threat. The company has made strides with its FDA-approved products, particularly NUZYRA® (omadacycline), a tetracycline-class antibiotic that addresses unmet medical needs in treating community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). NUZYRA® is available in both oral and intravenous formulations, showcasing Paratek's commitment to providing effective treatment options for serious bacterial infections caused by susceptible microorganisms. Additionally, the company is involved in ongoing research to explore further applications of NUZYRA® in areas of unmet medical need, including studies related to anthrax under a contract with the Department of Defense.

In addition to NUZYRA®, Paratek has developed SEYSARA® (sarecycline), which is approved for treating inflammatory lesions of moderate to severe acne vulgaris. The company retains global rights to sarecycline outside the U.S. and Greater China, where it is exploring partnership opportunities for further development and commercialization. Paratek's approach to tackling AMR includes a multi-faceted strategy that emphasizes responsible antibiotic use, enhanced surveillance, and research into new antibiotics, reflecting its dedication to addressing this critical public health issue and contributing to national security.

United States

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.

Infectious Diseases

Lung Diseases

Paratek Pharmaceuticals

Community acquired bacterial pneumonia

Pneumonia

Omadacycline is an aminomethylcycline antibacterial within the tetracycline class of antibacterial drugs. Omadacycline binds to the 30S ribosomal subunit and blocks protein synthesis. Omadacycline is active in vitro against Gram positive bacteria expressing tetracycline resistance active efflux pumps (tetK and tet L) and ribosomal protection proteins (tet M). In general, omadacycline is considered bacteriostatic; however, omadacycline has demonstrated bactericidal activity against some isolates of S. pneumoniae and H. influenzae.

Nuzyra (Omadacycline) 

Bacterial infection

Nuzyra (Omadacycline)

Acne

Acne vulgaris

Skin disease/disorder

The mechanism of action of SEYSARA in treating acne vulgaris is not known.

Seysara (Sarecycline)

Digestive tract

Intestinal infection

Nontuberculous mycobacteria infections

Stomach

NUZYRA &nbsp;(omadacycline) is a novel antibiotic with both once-daily oral and &nbsp;intravenous formulations for the treatment of community-acquired &nbsp;bacterial pneumonia (CABP) and acute bacterial skin and skin structure &nbsp;infections (ABSSSI). A modernized tetracycline, NUZYRA is specifically &nbsp;designed to overcome tetracycline resistance and exhibits activity &nbsp;across a spectrum of bacteria, including Gram-positive, Gram-negative, &nbsp;atypicals, and other drug-resistant strains.
<a href="https://www.paratekpharma.com/investor-relations/press-release?i=97587">Source</a>

Paratek Pharmaceuticals

Company Details